Ambrx Biopharma Inc.
NYSE:AMAM
28 (USD) • At close March 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets: | |||||||||
| Current Assets: | |||||||||
| Cash & Cash Equivalents
| 225.262 | 228.265 | 149.584 | 55.61 | 55.61 | 65.642 | 170.064 | 167.201 | 90.462 |
| Short Term Investments
| 0 | 6.824 | 7.94 | 28.873 | 28.873 | 45.251 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 225.262 | 235.089 | 157.524 | 84.483 | 84.483 | 110.893 | 170.064 | 167.201 | 90.462 |
| Net Receivables
| 2.357 | 2.312 | 2.316 | 2.05 | 0.376 | 2.237 | 1.343 | 0.888 | 0.982 |
| Inventory
| 5.394 | 3.031 | 2.864 | 3.731 | 0 | 6.89 | 5.169 | 4.679 | 1.442 |
| Other Current Assets
| 0.805 | 0.981 | 0.238 | 0.319 | 5.724 | 0.986 | 0.23 | 0.261 | 0.191 |
| Total Current Assets
| 233.818 | 241.413 | 162.942 | 90.583 | 90.583 | 121.006 | 176.806 | 173.029 | 93.077 |
| Non-Current Assets: | |||||||||
| Property, Plant & Equipment, Net
| 12.568 | 13.239 | 13.4 | 14.012 | 14.012 | 15.006 | 15.721 | 2.957 | 3.491 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 24.778 | 24.935 | 25.093 | 25.25 | 25.25 | 25.565 | 35.962 | 37.337 | 36.829 |
| Goodwill and Intangible Assets
| 24.778 | 24.935 | 25.093 | 25.25 | 25.25 | 25.565 | 35.962 | 37.337 | 36.829 |
| Long Term Investments
| 0 | 0 | 8.798 | 16.793 | 16.793 | 18.827 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 0.336 | 0.357 | 0.38 | 0.339 | -56.055 | 0.466 | 0.53 | 0.402 | 0.624 |
| Total Non-Current Assets
| 37.682 | 38.531 | 47.671 | 56.394 | 56.055 | 59.864 | 52.213 | 40.696 | 40.944 |
| Total Assets
| 271.5 | 279.944 | 210.613 | 146.977 | 146.977 | 180.87 | 229.019 | 213.725 | 134.021 |
| Liabilities & Equity: | |||||||||
| Current Liabilities: | |||||||||
| Account Payables
| 5.141 | 6.362 | 7.107 | 3.205 | 3.205 | 5.696 | 5.272 | 3.768 | 2.82 |
| Short Term Debt
| 1.915 | 1.854 | 1.793 | 1.734 | 0 | 1.32 | 0.915 | 1.67 | 1.595 |
| Tax Payables
| 2.252 | 2.189 | 1.917 | 1.703 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0.407 | 0.407 | 0.407 | 0.407 | 0 | 3.137 | 4.267 | 4.314 | 6.47 |
| Other Current Liabilities
| 10.805 | 9.556 | 6.782 | 11.314 | 13.455 | 15.585 | 14.125 | 7.732 | 2.375 |
| Total Current Liabilities
| 18.268 | 18.179 | 16.089 | 16.66 | 16.66 | 25.738 | 24.579 | 17.484 | 13.26 |
| Non-Current Liabilities: | |||||||||
| Long Term Debt
| 8.608 | 9.163 | 9.71 | 10.245 | 0 | 11.251 | 12.212 | 0.74 | 1.598 |
| Deferred Revenue Non-Current
| 1.342 | 1.342 | 1.342 | 1.342 | 0 | 1.109 | 1.381 | 1.757 | 3.261 |
| Deferred Tax Liabilities Non-Current
| 0.88 | 0.88 | 0.88 | 0.88 | 0 | 0.88 | 0.88 | 0.88 | 0.88 |
| Other Non-Current Liabilities
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.067 | 253.169 |
| Total Non-Current Liabilities
| 10.83 | 11.385 | 11.932 | 12.467 | 0 | 13.24 | 14.473 | 3.444 | 258.908 |
| Total Liabilities
| 29.098 | 29.564 | 28.021 | 29.127 | 29.127 | 38.978 | 39.052 | 20.928 | 272.168 |
| Equity: | |||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0.763 | 0 | 0 |
| Common Stock
| 0.006 | 0.043 | 0.039 | 0.027 | 0.027 | 0.027 | 0.027 | 0.024 | 0 |
| Retained Earnings
| -347.745 | -324.756 | -306.93 | -291.628 | -291.628 | -265.121 | -213.632 | -174.563 | -145.553 |
| Accumulated Other Comprehensive Income/Loss
| -0.79 | -0.953 | -0.976 | -1.302 | 0 | -1.007 | -0.79 | -0.79 | -0.686 |
| Other Total Stockholders Equity
| 590.931 | 576.046 | 490.459 | 410.753 | 409.451 | 407.993 | 403.599 | 368.126 | 6.805 |
| Total Shareholders Equity
| 242.402 | 250.38 | 182.592 | 117.85 | 117.85 | 141.892 | 189.967 | 192.797 | -139.434 |
| Total Equity
| 242.402 | 250.38 | 182.592 | 117.85 | 117.85 | 141.892 | 189.967 | 192.797 | -139.434 |
| Total Liabilities & Shareholders Equity
| 271.5 | 279.944 | 210.613 | 146.977 | 146.977 | 180.87 | 229.019 | 213.725 | 134.021 |